相关实验视频
Updated: Jun 11, 2025

08:51
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
8.9K
多发性硬化和COVID-19:风险,严重程度和与疾病修饰疗法的关联概述
Mary Hollist1, Abraham Hollist2, Katherine Au3
1Atrium Health, Concord, NC, USA.
Neuroscience insights
|September 30, 2024
概括
冠状病毒疾病2019 (COVID-19) 影响中枢神经系统,对多发性硬化症 (MS) 患者构成风险. 一些MS患者在COVID-19感染后出现神经症状,复发或疾病严重程度.
科学领域:
- 神经学 神经学
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
背景情况:
- 严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2) 导致COVID-19,这是一个全球卫生危机,最初被称为呼吸系统疾病.
- 新出现的证据表明,COVID-19显著影响中枢神经系统.
- 患有先前存在的神经疾病的患者,如多发性硬化症 (MS),特别容易受到伤害.
研究的目的:
- 审查COVID-19的神经表现的情况.
- 分析COVID-19对多发性硬化症 (MS) 患者的影响,特别是那些接受疾病修饰疗法的患者.
- 探索MS和SARS-CoV-2之间的关联,包括神经侵入性,发病性,疾病严重程度和结果.
主要方法:
- 综合文献综述. 这是一个全面的文献综述.
- 对MS患者COVID-19的神经学影响的研究结果的分析.
- 检查影响疾病严重程度和结果的因素.
主要成果:
- 在某些多发性硬化患者中,COVID-19可能会导致严重的神经并发症.
- 许多患有COVID-19的多发性硬化症患者会出现新的或恶化的神经症状.
- 在患有COVID-19的MS患者中观察到疾病复发和严重程度增加的风险.
结论:
- 虽然管理方面的进步 (疫苗接种,抗病毒药物) 已经减少了COVID-19的整体影响,但多发性硬化症患者仍然面临风险.
- 晚期多发性硬化症患者,特别是那些接受抗CD20治疗和现有残疾的患者,面临更高的风险.
- 持续的警和量身定制的护理对于在脆弱的多发性硬化症患者小组中管理COVID-19至关重要.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Parkinson's Disease: Overview
492
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
492
Rheumatic Heart Disease III: Medical Management
3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
T Cell Types and Functions
959
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
959
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
8
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
8
Atherosclerosis II: Clinical manifestations and prevention
2
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
2

